Seeking Alpha

Alexion Pharmaceuticals (ALXN -3.3%) dips after Citigroup intitiates coverage with a tepid...

Alexion Pharmaceuticals (ALXN -3.3%) dips after Citigroup intitiates coverage with a tepid Neutral rating, saying its current risk/reward profile isn't attractive. The firm notes that ALXN is presently trading at a very high P/E multiple that reflects optimistic expectations for upward EPS revisions. If history is a guide, the company will need to post significant upside surprises to offset the natural multiple contraction that is likely ahead.
From other sites
Comments (1)
  • cnylax44
    , contributor
    Comments (125) | Send Message
     
    WOW----leading edge research ! I wonder if this "analyst" will be one of the 11,000 employees on the chopping block ?
    7 Dec 2012, 12:47 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs